Therapeutic amprenavir concentrations in cerebrospinal fluid

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 4, 2012, Pages 1985-1989

  Croteau, David ^a   Letendre, Scott ^b   Best, Brookie M ^c,e   Rossi, Steven S ^c   Ellis, Ronald J ^a   Clifford, David B ^f   Collier, Ann C ^g   Gelman, Benjamin B ^h   Marra, Christina M ^g   McArthur, Justin ⁱ   McCutchan, J Allen ^b   Morgello, Susan ^j   Simpson, David M ^j   Way, Lauren ^d   Capparelli, Edmund ^c   Grant, Igor ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f WASHINGTON UNIVERSITY   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY   (United States)

^j MOUNT SINAI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; FOSAMPRENAVIR; RITONAVIR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM; DRUG CEREBROSPINAL FLUID LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; IC 50; MALE; PRIORITY JOURNAL; TREATMENT DURATION; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARBAMATES; CD4-POSITIVE T-LYMPHOCYTES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MIDDLE AGED; SULFONAMIDES; TANDEM MASS SPECTROMETRY;

EID: 84858654878     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05098-11     Document Type: Article

References (23)

1. Bachmeier CJ, Spitzenberger TJ, Elmquist WF, Miller DW. 2005. Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier. Pharm. Res. 22:1259-1268. (Pubitemid 41176029)
2. Best BM, et al. 2009. Low atazanavir concentrations in cerebrospinal fluid. AIDS 23:83-87.
3. Capparelli EV, et al. 2005. Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS 19:949-952. (Pubitemid 40834938)
4. Cysique LA, et al. 2009. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 73:342-348.
5. Ellis RJ, et al. 2000. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology 54:927-936. (Pubitemid 30111354)
6. Ellis RJ, et al. 1997. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann. Neurol. 42:679-688. (Pubitemid 27481539)
7. Ellis RJ, et al. 2002. Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch. Neurol. 59:923-928. (Pubitemid 34640751)
8. Heaton RK, et al. 2011. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J. Neurovirol. 17:3-16.
9. Kis O, Robillard K, Chan GNY, Bendayan R. 2010. The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharm. Sci. 31:22-35.
10. Letendre S, et al. 2008. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch. Neurol. 65:65-70.
11. Letendre SL, Capparelli EV, Ellis RJ, McCutchan JA. 2000. Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. The HIV Neurobehavioral Research Center Group. Antimicrob. Agents Chemother. 44:2173-2175. (Pubitemid 30484445)
12. Letendre SL, et al. 2004. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann. Neurol. 56:416-423. (Pubitemid 39166561)
13. Letendre SL, et al. 2007. Lopinavir with ritonavir reduces the HIV RNA level in cerebrospinal fluid. Clin. Infect. Dis. 54:1511-1517. (Pubitemid 351411885)
14. Marra CM, et al. 2009. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23: 1359-1366.
15. Masliah E, Heaton RK, Marcotte et al. 1997. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. Ann. Neurol. 42:963-972. (Pubitemid 28008427)
16. McArthur JC, et al. 1997. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann. Neurol. 42:689-698. (Pubitemid 27481540)
17. Parkin NT, et al. 2004. Natural variation of drug susceptibility in wildtype human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48:437-443. (Pubitemid 38141699)
18. Sadler B, et al. 2001. Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir. Antimicrob. Agents Chemother. 45:3663-3668. (Pubitemid 33107904)
19. Saumoy M, et al. 2011. Viral response in stable patients switching to fosamprenavir/ritonavir monotherapy (the FONT Study). HIV Med. 12: 438-441.
20. Sevigny JJ, et al. 2004. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 63:2084-2090. (Pubitemid 39636256)
21. Tozzi V, et al. 2009. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J. Acquir. Immune Defic. Syndr. 52:56-63.
22. Varatharajan L, Thomas SA. 2009. The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res. 82:A99-A109.
23. Wiley C, Schrier R, Nelson J, Lampert PW, Oldstone MB. 1986. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc. Natl. Acad. Sci. U. S. A. 83:7089-7093. (Pubitemid 16002375)